期刊
DIABETES OBESITY & METABOLISM
卷 11, 期 5, 页码 445-454出版社
WILEY
DOI: 10.1111/j.1463-1326.2008.00986.x
关键词
adiponectin; cardiovascular disease; metabolic syndrome
资金
- Swiss National Science Foundation [320080-105836]
- European Community
Changes in diagnostic criteria have impacted on the definition of the metabolic syndrome. The central aetiological importance of insulin resistance has lessened, while the role of other cardiovascular risk factors has progressively increased. Inflammatory mediators have also been identified as crucial targets for more selective therapies in metabolic syndrome. Among several pro-inflammatory factors, adiponectin has been shown to be associated with reduced cardiovascular risk in metabolic syndrome patients. Here, we review new therapeutic approaches, which could potentially increase adiponectin levels in metabolic syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据